FDA approves Ipsen’s Bylvay for cholestatic pruritus due to ALGS
Pharmaceutical Technology
JUNE 14, 2023
Bylvay is a once-a-day, non-systemic ileal bile acid transport inhibitor (IBATi) that acts locally in the small intestine and has minimal systemic exposure. The therapy is being offered immediately through prescription for eligible ALGS patients. More than 90% of patients who received treatment with odevixibat were pruritus responders.
Let's personalize your content